Molecules and methods for inhibiting shedding of KIM-1
View Patent ↗Disclosed are antibodies that inhibit proteolytic release of a soluble KIM-1 polypeptide from KIM-1 expressing cells. Also disclosed are methods of using the antibodies to inhibit shedding of the KIM-1 polypeptide.
1. A method of inhibiting release of a soluble form of KIM-1 from a cell expressing a KIM-1 cell surface polypeptide, the method comprising contacting a cell expressing a KIM-1 cell surface polypeptide with an effective amount of an isolated antibody or antigen-binding-fragment thereof that binds to the extracellular domain of the human KIM-1 polypeptide of SEQ ID NO:7 at an epitope within or overlapping the amino acid sequence: SSDGLWNNNQTQLFLEHS (SEQ ID NO:1).
2. The method of claim 1 , wherein the cell is a renal cell.
3. The method of claim 1 , wherein the cell is in vitro.
4. The method of claim 1 , wherein the cell is in vivo.
5. A method of inhibiting proteolysis of a KIM-1 polypeptide, the method comprising contacting a cell expressing a KIM-1 polypeptide with an effective amount of an isolated antibody or antigen-binding-fragment thereof that binds to the extracellular domain of the human KIM-1 polypeptide of SEQ ID NO:7 at an epitope within or overlapping the amino acid sequence: SSDGLWNNNQTQLFLEHS (SEQ ID NO:1).
6. The method of claim 1 , wherein the antibody has the same epitope specificity as the antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA-3350.
7. The method of claim 1 , wherein the antibody crossblocks binding of the antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA-3350.
8. The method of claim 1 , wherein the antibody is produced by the hybridoma deposited in the ATCC under Accession No. PTA-3350.
9. The method of claim 1 , wherein the antibody binds to the extracellular domain of the human KIM-1 polypeptide of SEQ ID NO:7 at an epitope within the amino acid sequence: SSDGLWNNNQTQLFLEHS (SEQ ID NO:1).
10. The method of claim 1 , wherein the antibody is a humanized antibody.
11. The method of claim 1 , wherein the antibody is a fully human antibody.
12. The method of claim 1 , wherein the antibody is a monoclonal antibody.
13. The method of claim 1 , wherein the antibody is a single chain antibody.
14. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, a chimeric antibody, an F ab fragment, an F (ab′)2 fragment, an F ab ′ fragment, an F sc fragment, or an F v fragment.
15. The method of claim 5 , wherein the antibody has the same epitope specificity as the antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA-3350.
16. The method of claim 5 , wherein the antibody crossblocks binding of the antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA-3350.
17. The method of claim 5 , wherein the antibody is produced by the hybridoma deposited in the ATCC under Accession No. PTA-3350.
18. The method of claim 5 , wherein the antibody binds to the extracellular domain of the human KIM-1 polypeptide of SEQ ID NO:7 at an epitope within the amino acid sequence: SSDGLWNNNQTQLFLEHS (SEQ ID NO:1).
19. The method of claim 5 , wherein the antibody is a humanized antibody.
20. The method of claim 5 , wherein the antibody is a fully human antibody.
21. The method of claim 5 , wherein the antibody is a monoclonal antibody.
22. The method of claim 5 , wherein the antibody is a single chain antibody.
23. The method of claim 5 , wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, a chimeric antibody, an F ab fragment, an F (ab′)2 fragment, an F ab ′ fragment, an F sc fragment, or an F v fragment.